4
Changes in Ownership
VERTEX PHARMACEUTICALS INC / MA Filed Acc 0001209191-23-024312
EVP, Cell & Genetic Therapies sold 7,567 shares at an average $326.70 ($2,472,164)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Sanna Bastiano · EVP, Cell & Genetic Therapies
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-12 | Sale : show line 1 in the form 10b5-1 | −874 | $325.70 | $284,662 | 46,406 | D |
| 2023-04-12 | Sale : show line 2 in the form 10b5-1 | −4,068 | $326.45 | $1,327,999 | 42,338 | D |
| 2023-04-12 | Sale : show line 3 in the form 10b5-1 | −2,625 | $327.43 | $859,504 | 39,713 | D |
| Open-market sales · 7,567 sh · avg $326.70 · $2,472,164 | ||||||
Loading xslF345X04/doc4.xml…